The Spanish contribution to the European Randomized Study of Screening for Prostate Cancer

BJU International, Supplement

Volumn 92, Issue 2, 2003, Pages 33-38

  Berenguer, A ^a   Lujan M ^a   Paez A ^a   Santonja, C ^a   Pascual, T ^a  

^a HOSPITAL UNIVERSITARIO DE GETAFE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

HORMONE; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BEAM THERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SCREENING; CAUSE OF DEATH; CLINICAL TRIAL; CONTAMINATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC TEST; DIGITAL RECTAL EXAMINATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTASIS; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL; SPAIN; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY;

AGE OF ONSET; AGED; BIOPSY; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SPAIN;

EID: 0347756706     PISSN: 14655101     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. http://www.ine.es, last accessed 24 February 2003
2. de Köning HJ, Auvinen A, Berenguer A et al. Large-scale randomized prostate cancer screening trials: program performances in the European Randomized Screening for Prostate Cancer trial and the Prostate, Lung, Colorectal and ovary cancer trial. Int J Cancer 2002; 97: 237-44
3. Benson MC, Whang IS, Pantuck A et al. Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 1992; 147: 815-6
4. Martin E, Luján M, Sánchez E, Herrero A, Páez A, Berenguer A. Final results of a screening campaign for prostate cancer. Eur Urol 1999; 35: 26-31
5. Luján M, Páez A, Llanes L, Miravalles E, Berenguer A. Prostate specific antigen density. Is there a role for this parameter when screening for prostate cancer? Prostate Cancer Prostatic Dis 2001; 4: 146-9
6. Carter HB, Pearson JD, Metter JE et al. Longitudinal evaluation of prostate-specific antigen levels in men with and without prostate disease. JAMA 1992; 267: 2215-20
7. Luján M, Páez A, Sánchez E, Herrero A, Martin E, Berenguer A. Prostate specific antigen variation in patients without clinically evident prostate cancer. J Urol 1999; 162: 1311-3
8. Oesterling JE. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA 1993; 270: 860-4
9. Lilja H. Significance of different molecular forms of serum PSA; the free, non-complexed form of PSA versus that complexed to alpha-1- antichymotripsin. Urol Clin North Am 1993; 20: 681-6
10. Brawer MK, Cheli CD, Neaman IE, et al. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J Urol 2000; 163: 1476-80
11. Llanes L, Páez A, Ferruelo A, Luján M, Romero I, Berenguer A. Detecting prostate cells in patients with clinically localized prostate cancer; clinical implications for molecular staging. BJU Int 2000; 86: 1023-7
12. Páez A, Luján M, Llanes L et al. PSA use in a Spanish industrial area. Eur Urol 2002; 41: 162-6
13. Sánchez-Chapado M, Olmedilla G, Cabeza M, Donat E, Ruiz A. Prevalence of prostate cancer and prostatic intraepithelial neoplasia in Caucasian Mediterranean males: an autopsy study. Prostate 2003; 15: 238-47
14. Romero I, Páez A, Ferruelo A, Luján M, Berenguer A. Polyphenols in red wine inhibit the proliferation and induce apoptosis of LNCaP cells. BJU Int 2002; 89: 950-4